ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Trian Presses For Seats On DuPont’s Board

by Alexander H. Tullo
February 16, 2015 | APPEARED IN VOLUME 93, ISSUE 7

The conflict between DuPont and Trian Partners, the hedge fund run by activist investor Nelson Peltz, appears to be headed to a proxy fight at DuPont’s annual meeting later this year. Earlier this month, DuPont attempted to scuttle Trian’s efforts by naming two seasoned executives—James L. Gallogly, former CEO of LyondellBasell Industries, and Edward D. Breen, chairman of Tyco International—to replace two outgoing directors. The company also rejected three of four Trian nominees to the board, including Peltz. Trian, which controls a 2.7% stake in DuPont, is standing by its nominees. Trian also set up a website, DuPontCanBeGreat.com, to distribute information to DuPont shareholders. On this website, Trian posted a new, 78-page, white paper critiquing DuPont, repeating arguments that DuPont is stymied by too much overhead, that its shareholder returns have been subpar, and that some of its strategic moves—including the sale of its coatings business to a private equity firm—have been missteps. Trian also struck a conciliatory tone, softening its argument that DuPont needs to be broken up. “Trian nominees are open-minded to keeping the portfolio together if performance can be improved,” the hedge fund noted.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment